Navigation Links
Renhuang Pharmaceuticals Announces Plans to Introduce Qing Re Jie Du Oral Liquid
Date:4/29/2010

HARBIN, China, April 29 /PRNewswire-Asia-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) ("Renhuang" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced the Company plans to launch Qing Re Jie Du Oral Liquid ("Qing"), a traditional Over-the-Counter ("OTC") Chinese Medicine for the treatment of influenza ("the flu") and upper respiratory infections in June 2010.

Qing is an all-natural, plant-based traditional OTC Chinese Medicine with proven benefits in treating the flu, upper respiratory infections, and sore throats. The Company expects Qing to generate $1.0 million to $1.5 million in revenues in fiscal 2010.

"We have great confidence in the performance and effectiveness of our latest product, Qing Re Jie Du Oral Liquid, and anticipate positive market acceptance," said Mr. Shaoming Li, the Chairman and CEO of Renhuang. "Qing's all-natural active ingredients are effective against flu symptoms and cause no side effects associated with chemical drugs. At Renhuang, we are committed to developing superior products which meet the needs of our customers and we are equally committed to creating value for our shareholders. In this pursuit, we continue to expand our product portfolio to boost our revenue stream and fuel Renhuang's growth."

ABOUT RENHUANG PHARMACEUTICALS, INC.

Renhuang Pharmaceuticals, Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. Company Website: http://www.renhuang.com

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to achieve its revenue and growth forecast for Qing Re Jie Du Oral Liquid, the Company's ability to achieve its financial guidance, ability to continue to improve its days sales outstanding, ability to list its shares on a senior stock exchange, ability to manage expansion of its operations effectively, competition in the marketing and sales of its products, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward- looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

    Company Contact:

    Renhuang Pharmaceuticals, Inc.
     Ms. Portia Tan, IR Contact
     Tel:   +86-451-5392-5461
     Email: ir@renhuang.com

    CCG Investor Relations:
     Ms. Lei Huang, Account Manager
     Tel:   +1-646-833-3417 (New York)
     Email: lei.huang@ccgir.com
     Web:   www.ccgirasia.com

     Mr. Crocker Coulson, President
     Tel:   +1-646-213-1915 (New York)
     Email: crocker.coulson@ccgir.com


'/>"/>
SOURCE Renhuang Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Renhuang Appoints New Director and Establishes Nominating and Compensation Committee
2. Renhuang Pharmaceuticals Announces Continual Improvement in Days Sales Outstanding
3. Renhuang Schedules Conference Call to Discuss FY 2010 First Quarter Results
4. Renhuang Announces Price Increase on Shengmai Granules
5. Renhuang Announces Fiscal Year 2010 Guidance
6. Jazz Pharmaceuticals to Announce First Quarter 2010 Financial Results on May 5, 2010
7. Cumberland Pharmaceuticals Partners in Canada With Alveda Pharmaceuticals to Commercialize Caldolor(R)
8. Onyx Pharmaceuticals Announces First Quarter 2010 Financial Results Teleconference and Webcast
9. Jazz Pharmaceuticals to Present at Deutsche Banks 35th Annual Health Care Conference
10. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
11. Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... , May 3, 2016  While you may be familiar with watching a film or ... also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is a renowned authorized ... innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
(Date:5/3/2016)... Inc. (NYSE: DPLO) announced today that it is celebrating Hepatitis Awareness Month with a campaign ... their personal story and encourage those at risk to get tested and begin the road ... ... ... Pharmacy (PRNewsFoto/Diplomat Pharmacy, Inc.) ...
(Date:5/3/2016)... 3, 2016 According to market ... Development, Growth and Demand Forecast to 2022 - Industry ... (High Field, Very High Field, Low to Mid Field, ... Neck, Spine, Musculoskeletal, Vascular, Breast, Pelvic and Abdomen, Cardiac, ... imaging (MRI) market was valued at $5,351.7 million in ...
Breaking Medicine Technology:
(Date:5/5/2016)... , ... May 05, 2016 , ... Einstein Medical ... Twitter feed to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium ... meeting of the American Society of Cataract and Refractive Surgery and the American Society ...
(Date:5/5/2016)... ... May 05, 2016 , ... TLC Laser Eye Centers ... California. The laser eye center will now be called “Gordon Schanzlin New Vision Institute, ... will remain at the full-service facility to ensure that patients continue to receive the ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... successful results with IVF and with egg freezing, today announced the grand opening ... and highest quality fertility care, Spring Fertility offers both fertility preservation (egg, sperm, ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... Seminars for Business Journalists , led by the Wharton School’s most prominent ... issues.  This one-day program at the Wharton School’s San Francisco campus will ...
(Date:5/5/2016)... Indianapolis, IN (PRWEB) , ... May 05, 2016 ... ... employee benefits advisory organization, announces McLaughlin & Smoak Benefits as the latest addition ... & Smoak Benefits has a dedicated team of compliance, wellness, human resources, and ...
Breaking Medicine News(10 mins):